Core Viewpoint - Theralase Technologies Inc. is hosting a conference call on November 19, 2025, to update investors on the interim data from its Phase II clinical study for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, along with financial and operational results for Q3 2025 [1][3]. Study II Update - As of November 7, 2025, Theralase is on track to complete enrollment in Q4 2025, with data lock and regulatory submissions expected in Q1 2027 [3]. - 88 patients have been treated, representing 97.8% of the targeted enrollment of 90 patients [6]. - 64.3% (54 out of 84) of patients achieved a Complete Response (CR) at any point, while 72.6% (61 out of 84) achieved a Total Response (TR) [6]. - At the 450-day assessment, 40% (18 out of 45) maintained a CR, and 42.2% (19 out of 45) maintained a TR, indicating durability of response [6]. Financial Update - Revenue decreased by 5% to $590,573 from $622,984, while the cost of sales decreased by 10% to $299,743, representing 51% of revenue [14]. - Gross margin remained stable at $290,830, which is 49% of revenue [14]. - Selling expenses decreased by 18% to $212,421, while administrative expenses increased by 12% to $1,444,687 [14]. - Research and development expenses increased by 1% to $2,116,540, reflecting increased activity for Study II [14]. - The net loss increased by 3% to $3,435,145, including $708,521 in non-cash expenses [14]. - The company raised $672,627 via a non-brokered private placement and has $280,000 in outstanding short-term loans at 15% interest as of November 7, 2025 [14].